Palisade Bio vs Yarrow Bioscience
PALI and YARW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PALI and YARW compare
Palisade Bio and Yarrow Bioscience are about the same size, with market caps of $195M and $207M.
Yarrow Bioscience keeps more of each dollar of sales as profit, with a net margin of −4646% compared with −8739% at Palisade Bio.
Yarrow Bioscience pays a dividend yielding 112%; Palisade Bio does not pay one.
Yarrow Bioscience scores higher on the StockData Score (13 against 6 for Palisade Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PALI | YARW |
|---|---|---|
| Size and price | ||
| Market cap | $195M | $207M |
| Share price | $1.12 | $18.03 |
| Change, 1 year | −45.1% | 2.4% |
| Change, 5 years | −99.9% | −98.1% |
| Beta (5Y) | 0.97 | 1.55 |
| Employees | 100K | 10 |
| StockData Score | ||
| Total score | 6 | 13 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/S | 390× | 363× (better) |
| P/B | 1.7× | 0.8× (better) |
| FCF yield | – | −16.0% |
| Growth | ||
| Revenue growth (TTM) | – | 13.8% |
| Revenue growth, 5Y average | – | −51.4% |
| Profitability | ||
| Operating margin | −9625% | −5219% (better) |
| Net margin | −8739% | −4646% (better) |
| FCF margin | – | −5811% |
| Return on equity | −75.6% | −16.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −16042.3× | – |
| Current ratio | 20.16 | 42.08 (better) |
| Altman Z-score | 18.98 | 19.42 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 112% |
| Buyback yield | −67.5% | – |
| Shareholder yield | −67.5% | 112% (better) |
| Ownership | ||
| Held by institutions | 99.5% | 2.7% |
| Held by insiders | 4.7% | 19.1% |
| Insider net buying, 12 months | −$124K | – |
| Short interest, % of float | 17.6% | 1.5% |
Go deeper
- PALI stock overview
- PALI income statement
- PALI valuation and score
- YARW stock overview
- YARW income statement
- YARW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.